Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO
NASDAQ
2.06
USD
0.49%
About
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM).
Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 269.2K |
| Three Month Average Volume | 7.6M |
| High Low | |
| Fifty-Two Week High | 14.748 USD |
| Fifty-Two Week Low | 3.888 USD |
| Fifty-Two Week High Date | 01 Apr 2024 |
| Fifty-Two Week Low Date | 10 Nov 2023 |
| Price and Volume | |
| Current Price | 7.22 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -27.99% |
| Thirteen Week Relative Price Change | -33.41% |
| Twenty-Six Week Relative Price Change | -31.24% |
| Fifty-Two Week Relative Price Change | 6.72% |
| Year-to-Date Relative Price Change | -0.38% |
| Price Change | |
| One Day Price Change | -1.37% |
| Thirteen Week Price Change | -28.73% |
| Twenty-Six Week Price Change | -24.40% |
| Five Day Price Change | -3.86% |
| Fifty-Two Week Price Change | 33.73% |
| Year-to-Date Price Change | 17.97% |
| Month-to-Date Price Change | -32.27% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.14845 USD |
| Book Value Per Share (Most Recent Quarter) | 3.72596 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.14845 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.72596 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.80179 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.03752 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.02476 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -6.0936 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.10904 USD |
| Normalized (Last Fiscal Year) | -5.61946 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -6.0936 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.10904 USD |
| Including Extraordinary Items (Last Fiscal Year) | -6.0936 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.10904 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.37447 USD |
| Cash Per Share (Most Recent Quarter) | 4.25295 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.96881 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -5.00011 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.72106 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -3,432 |
| Cash Flow Revenue (Trailing Twelve Months) | -19,066 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -20,552.24% |
| Pretax Margin (Last Fiscal Year) | -16,239.87% |
| Pretax Margin (5 Year) | -4,098.42% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -17,300.28% |
| Operating Margin (Trailing Twelve Months) | -21,563.99% |
| Operating Margin (5 Year) | -3,866.88% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -16,239.87% |
| Net Profit Margin (Trailing Twelve Months) | -20,552.24% |
| Net Profit Margin (5 Year) | -4,097.36% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.66% |
| Tangible Book Value (5 Year) | 10.37% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -55.41% |
| Revenue Growth (3 Year) | -51.33% |
| Revenue Change (Trailing Twelve Months) | -93.85% |
| Revenue Per Share Growth | -60.60% |
| Revenue Growth (5 Year) | -51.76% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -31.22% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 26.52% |
| EPS Change (Trailing Twelve Months) | 35.55% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -110,421,500 |
| Net Debt (Last Fiscal Year) | -128,523,100 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 225 |
| Price to Sales (Trailing Twelve Months) | 317 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -124,686,400 |
| Free Cash Flow (Trailing Twelve Months) | -112,843,600 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 14 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -52.02% |
| Return on Assets (Trailing Twelve Months) | -66.32% |
| Return on Assets (5 Year) | -59.52% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -79.55% |
| Return on Equity (Trailing Twelve Months) | -91.42% |
| Return on Equity (5 Year) | -84.49% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -71.11% |
| Return on Investment (Trailing Twelve Months) | -84.33% |
| Return on Investment (5 Year) | -71.29% |